Azienda Unita Locale Socio Sanitaria N. 1 Dolomiti
- Address
- Via Bagnols Sur Ceze 3, 32032 Feltre, Italy
Neoplasms and Respiratory Oncology
At Azienda Unita Locale Socio Sanitaria N. 1 Dolomiti in Feltre, the cancer research portfolio focuses on advanced non-small-cell lung cancer. The studies are designed to evaluate whether new treatment combinations can improve survival and strengthen first-line care for people with this aggressive disease.
- Testing whether adding a second therapy can improve outcomes in untreated metastatic NSCLC
- Assessing the effectiveness of immunotherapy combinations for better disease control
- Supporting research aimed at extending overall survival in lung cancer
This work reflects a strong interest in advancing treatment strategies for patients with lung cancer, especially where more effective options are still needed.
Kidney Disease and Reproductive and Urinary Physiology
The site is also involved in research on chronic kidney disease, with studies exploring ways to slow progression and reduce serious complications. These trials are focused on protecting kidney function and improving long-term health for people living with chronic renal conditions.
- Evaluating new approaches to prevent worsening of chronic kidney disease
- Studying whether treatment combinations can lower the risk of heart failure hospitalization and cardiovascular death
- Investigating therapies that may help preserve kidney function over time
The research combines nephrology and cardiovascular protection, aiming to better understand how to improve outcomes for patients with kidney disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1AstraZeneca AB1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Unita Locale Socio Sanitaria N. 1 Dolomiti
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase II Randomized Trial of Atezolizumab Versus Atezolizumab Plus Bevacizumab in PD-L1 High Advanced Non-Small-Cell Lung Cancer | Fondazione Ricerca Traslazionale | Phase II | Recruiting | Jan 2020 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atezolizumab | 1 | Unknown | 2020-01-31 | 2020-01-31 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.